Prostate cancer (PrCa) is the most frequently diagnosed cancer in males in developed countries. To identify common PrCa susceptibility alleles, we previously conducted a genome-wide association study in which 541,129 SNPs were genotyped in 1,854 PrCa cases with clinically detected disease and in 1,894 controls. We have now extended the study to evaluate promising associations in a second stage in which we genotyped 43,671 SNPs in 3,650 PrCa cases and 3,940 controls and in a third stage involving an additional 16,229 cases and 14,821 controls from 21 studies. In addition to replicating previous associations, we identified seven new prostate cancer susceptibility loci on chromosomes 2, 4, 8, 11 and 22 (with P = 1.6 × 10 −8 to P = 2.7 × 10 −33 ).
Genome-wide association studies (GWAS) provide a powerful approach to identifying common disease alleles. We previously conducted a GWAS 1 based on genotyping of 541,129 SNPs in 1,854 individuals with clinically detected PrCa (cases) and 1,894 controls (see Fig. 1 , stage 1). Followup genotyping of SNPs showing strong evidence of association (P < 10 −6 ) in a further 3,268 cases and 3,366 controls allowed us to identify SNPs at seven susceptibility loci associated with the disease at genome-wide levels of significance 1 . Other studies have identified an additional eight loci associated with PrCa [2] [3] [4] [5] [6] [7] [8] [9] . These loci, however, explain only a small fraction of the familial risk of PrCa. Moreover, the strength of the associations that have been detected are generally small (per-allele odds ratios (OR) 1.1-1.2), and the power of the existing studies to detect many of the susceptibility alleles has been limited. It is highly likely, therefore, that other PrCa predisposition loci exist and that such loci should be detectable in studies with larger sample sizes.
In an attempt to identify additional susceptibility loci, we conducted a more extensive follow-up of SNPs showing evidence of association in stage 1 of our GWAS. We designed a panel of 47,120 SNPs, Identification of seven new prostate cancer susceptibility loci through a genome-wide association study aiming to include all SNPs with a significant association in stage 1 at P trend (1 degree of freedom (d.f.)) <0.05 or P (2 d.f.) <0.01 (see Online Methods). These SNPs were genotyped using the Illumina iSELECT platform in 3,894 PrCa cases and 4,055 controls from the United Kingdom (UK) and Australia (Fig. 1, stage 2 ). After quality control exclusions (as described in Online Methods), we used data from 43,671 SNPs in 3,650 PrCa cases and 3,940 controls.
Genotype frequencies in cases and controls were compared using a 1 d.f. Cochran-Armitage trend test (for quantile-quantile plots see Supplementary Fig. 1 ). There was little evidence of inflation in the test statistics in the UK samples (estimated inflation factor (l) = 1.08), but there was more marked inflation in those samples from Australia (l = 1.23; l = 1.19 for stage 2 overall), suggesting some population substructure. The Australian samples were selected from three studies (MCCS, RFPCS and EOPCS; see Supplementary Note for cohort descriptions), and further analysis revealed that adjustment for substudy substantially reduced the inflation (l = 1.08 for Australia, l = 1.14 overall). This inflation may reflect oversampling in MCCS for individuals of Southern European ancestry. Principal components analysis identified a distinct cluster that is overrepresented in the MCCS study, which is consistent with admixture in this population (see Online Methods and Supplementary Fig. 2) . Adjustment for the first two principal components in addition to stratification by substudy did not, however, reduce the inflation factor further. The residual inflation could reflect weak population substructure or the combined effects of weak susceptibility alleles.
There was a clear excess of nominally significant associations in stage 2, with 132 SNPs significant at P < 0.0001 compared with the approximately four significant SNPs that would be expected by chance (Supplementary Table 1) . After combining stage 2 data with the stage 1 data, 116 SNPs were significant at P < 10 −6 (Supplementary Table 2 ). Of these, 26 were on chromosome 8q24, a region known to harbor multiple PrCa susceptibility loci 1, 3, 4, 6, 7 . In addition, 42 SNPs were in the 7 regions we identified in our previous analysis 1 and 13 were in 2 regions on 17q identified by Gudmundsson et al. 5 . We also found strong evidence for an association with two SNPs on 2p15 (rs2710647, P = 7.1 × 10 −8 ; rs6545977, P = 4.5 × 10 −7 ) within the EHBP1 gene, a location close to that recently reported by Gudmundsson et al. 8 . rs2710647 is, however, only weakly correlated with the previously reported SNP rs721048 (r 2 = 0.19) and might reflect an independent association. Two additional susceptibility loci on chromosomes 7 and 10 were identified in the GWAS by Thomas et al. 9 . We found supporting evidence for an association with rs10486567 on chromosome 7 (JAZF1; stage 2 per-allele OR = 0.92, 95% CI = 0.85-1.00, combined P = 0.00008), but we found only limited evidence for an association with rs4962416 on chromosome 10 (CTBP2; per-allele OR = 1.05, 95% CI = 0.98-1.13, P = 0.04).
The remaining 33 SNPs significant at P < 10 −6 were in ten regions not previously associated with PrCa. Multiple logistic regression analysis was used to define a minimal subset of 12 independently significant SNPs such that the remaining SNPs were not significant after adjustment for these SNPs. The strength of these associations in stage 2 was not substantially affected by principal components adjustment (Supplementary Table 3 ). These 12 SNPs were then subjected to further replication analysis in a third stage involving 16,229 cases and 14,821 controls from 21 studies participating in the PRACTICAL (PRostate cancer AssoCiation group To Investigate Cancer Associated aLterations in the genome) Consortium (Supplementary Table 4) .
Eight SNPs in seven regions showed clear evidence of replication in stage 3 (P = 0.0002 or lower and with the effects for each SNP in the same direction as in stages 1 and 2). In each case the combined P trend over all 3 stages reached P < 10 −7 with a range of P = 1.6 × 10 −8 to P = 2.7 × 10 −33 (see Table 1 ). Two SNPs on chromosome 4, rs17021918 and rs12500426, were correlated (r 2 = 0.5), but both showed independent association after multiple logistic regression analyses (P = 0.014 and P = 0.0003 for the effect of rs12500426 after adjustment for rs17021918 in stage 3 and overall, respectively; P = 0.0002 and P = 3.6 × 10 −7 for the effects of rs17021918 after adjustment for rs12500426; Supplementary Table 5 ). In addition to the above SNPs, an additional SNP on chromosome 8 showed more limited evidence of replication (P = 0.007 in stage 3, P = 7.1 × 10 −8 overall). This SNP is ~90 kb from rs1512268, which showed very clear evidence of association (P = 3.4 × 10 −30 ), but the SNPs are in neighboring linkage disequilibrium (LD) blocks and are only weakly correlated (r 2 = 0.03). rs12155172 on chromosome 7 showed weak evidence of association in stage 3 (P = 0.06, with an effect in the same direction as stages 1 and 2) but did not reach genome-wide significance in the combined dataset (P = 8.8 × 10 −6 ). Thus, this locus may harbor a susceptibility allele, but further large case-control studies will be required to confirm or refute this finding. For the remaining two loci on chromosomes 12 and 16, there was no evidence of association in stage 3. We conclude that these two loci were probably false positive associations in stages 1 and 2.
We were able to compare our results with those from the Cancer Genetic Markers of Susceptibility (CGEMS) PrCa study, a GWAS of 1,117 PrCa cases and 1,105 controls that used the same genotyping platform as our GWAS. Of the 9 SNPs that reached genome-wide significance in our study, 8 were typed in Chr.
Potentially causative genes 
e t t e r s
CGEMS and all had an estimated OR in the same direction as our study (Supplementary Table 6 ). Only two of the SNPs were nominally significant in CGEMS (rs5759167; P = 0.0035 and rs7679673; P = 0.014). In all cases, however, the estimated 95% CI for the per-allele OR from the CGEMS study contained our estimate. This suggests that the failure to replicate association of some of these loci in CGEMS may be related to the relatively smaller size of the CGEMS stage 1. Odds ratio 0.6 0. 
l e t t e r s
All but two of the SNPs associated with PrCa risk show an association with allele dose that is consistent with a log-additive model, the model that is observed for most common cancer-susceptibility alleles. rs12621278 on chromosome 2 exhibits a strong dose response, with an OR in homozygotes (0.35, 95% CI = 0.24-0.52) that is smaller than would be expected under a log-additive model (P = 0.0076). rs17021918 on chromosome 4 showed no difference in risk between heterozygotes and homozygotes (P = 0.023 compared with a logadditive model).
There was no evidence for a difference in the per-allele ORs among European, Asian and African-American populations (Fig. 2) with the exception of rs12500426 on chromosome 4, which showed an association in Europeans but not in Asian or African-American studies (P = 0.046 for heterogeneity in the OR by population), and rs7679673 on chromosome 4, for which the association seen in European and Asian populations was not observed in African-Americans (P = 0.032). These might reflect differences in the LD structure or the frequency of the causal variant(s) in different populations. There was no evidence of heterogeneity in the per-allele ORs in European and African-American studies for any SNP, and there was only weak evidence of heterogeneity for two SNPs in Asian studies (Supplementary Table 7 ). We also found no marked differences in the per-allele ORs between studies based on populations where prostate-specific antigen (PSA) screening was prevalent (studies in the United States and the Prostate testing for cancer and Treatment (ProtecT) study in the United Kingdom) and those in which screening was less common (Supplementary Table 8) .
The controls in stage 1 of our GWAS were selected for low PSA levels, and this may have led to the preferential selection of SNPs associated with PSA levels 10, 11 . We were able to examine the associations between genotypes and serum PSA levels in 1,585 control samples from the ProtecT study in stage 2 of our scan (Supplementary l e t t e r s Table 9 ). Two SNPs, rs17021918 (chromosome 4) and rs1512268 (chromosome 8), showed weak association with PSA levels in the same direction as the PrCa association (P = 0.043 and P = 0.037, respectively). Both SNPs, however, showed very strong evidence of association in all three stages, and we conclude that none of the associations are likely to be mediated simply through associations with PSA level. Gleason score data were available for 7,855 PrCa cases from 14 studies. There was no difference in the OR for cases with high-or intermediategrade disease (Gleason score ≥7) versus low-grade disease (Gleason score <7) for any of the associated SNPs (Supplementary Table 10) . This consistency (also seen for the previously identified loci 1 ) suggests that most of the susceptibility loci identified so far modulate the early stages of disease development rather than disease progression.
For two of the SNPs, rs12621278 on chromosome 2 (P = 1.1 × 10 −5 ) and rs7127900 on chromosome 11 (P = 0.006), the per-allele OR varied with age; a higher OR was seen in subjects at younger ages (Supplementary Table 11 ). One SNP, rs7679673 on chromosome 4, also showed a stronger association when analyses were restricted to cases with a family history of PrCa (P = 0.02; Supplementary Table 12) .
The PrCa-associated SNPs identified in the second stage of our GWAS lie in LD blocks that include several plausible causative genes (see Fig. 1 for candidate gene list and Supplementary Note for details). Particularly notable are rs12621278 on 2q31, which is in intron 1 of ITGA6 (the gene encoding integrin alpha 6), and rs2928679 and rs1512268, which lie 90 kb apart on 8p21. rs2928679 lies 10 kb downstream of NKX3.1, which codes for an androgen-regulated homeobox protein NKX3.1 that is in the HDAC1 pathway.
Most of the per-allele ORs estimated for these variants in this study population were modest, ranging from 1.08-1.28. We found no other loci with associations as strong as the SNPs on 8q or the MSMB locus-as expected because the power to detect these loci in our first analysis was already high. Nevertheless, there are now more than 20 loci conferring ORs >1.1 for PrCa, which is more loci than for any other cancer types. We estimate that the power to detect these associations in this study varied from >80% (for rs1512268 and rs7127900) to <1% (for rs1465618, rs12155172 and rs2928679; Supplementary Table 13 ). This strongly suggests that additional loci with associations of similar magnitude remain to be identified. Mapping of such loci will require the synthesis and follow-up of larger GWAS datasets. We have demonstrated that we have power to confirm the associations with PrCa of such loci using the PRACTICAL Consortium.
On the assumption that there is an overall twofold familial relative risk to first-degree relatives of PrCa cases and that the SNPs combine multiplicatively, the newly associated loci reported here together explain ~4.3% of the familial risk of PrCa. Including the previously reported loci, ~21.5% of familial risk in PrCa may now be explained. Under this model, the top 10% of the population at highest risk for PrCa has a relative risk ~2.3-fold greater than the average risk in the general population , whereas the top 1% has an estimated threefold increased relative risk. In contrast, the individuals classified at the bottom 1% of genetic risk according to this model are estimated to have a relative risk of about one-fifth of the population average. Such risk prediction may have implications for targeted screening and prevention. Moreover, the associations we have found using tag SNPs may represent stronger associations with the causal variants. If so, the overall contribution of the causal variants will be greater. Resequencing of these regions, as well as further genotyping and functional analyses, will be required to identify the genetic variants responsible for each risk locus.
MeThodS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. 
Note: Supplementary information is available on the Nature Genetics website.
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Samples. PrCa cases and controls used in stage 1 of the GWAS have been described previously 1 . PrCa cases and controls for stage 2 ( Fig. 1) were selected from studies in the UK and Australia. UK cases were drawn from the UK Genetic Prostate Cancer Study (UKGPCS). UKGPCS includes PrCa cases that were either diagnosed at age ≤60 years (n = 341) and/or those that had a first-or second-degree family history of prostate cancer (n = 220). Study participants were recruited from urologists throughout the UK, and a series of cases was recruited from PrCa clinics in the Urology Unit at The Royal Marsden NHS Foundation Trust over a 14-year period. UK controls were identified through two sources. Six hundred fifty-six controls were drawn from the UKGPCS study (Prostate Cancer Research Foundation Study component) and were matched geographically, ethnically and for age to the UKGPCS young-onset cases. The controls had no family or personal history of PrCa. The remaining controls (n = 1,636) were selected from men in the ProtecT study 12 . ProtecT is a national study of community-based PSA testing and a randomized trial of subsequent PrCa treatment. Approximately 110,000 men between the ages of 50 and 69 years (with a small set of men aged 45-49 years from one center) were ascertained through general practices in nine regions in the UK. For this study, we selected as controls men who had a PSA of <10 ng/ml and negative prostate biopsies. Men with PSA ≥3 ng/ml were excluded if they had a positive prostatic biopsy. We excluded men who self-reported to be non-white from both cases and controls. The majority of men in the UK are diagnosed via a clinical presentation; among the cases in this study, 100% of those from the ProtecT study were diagnosed through asymptomatic PSA screening.
The Australian cases were ascertained from three studies [13] [14] [15] : (i) a population-based series of PrCa cases identified from the Victorian Cancer Registry since 1999, diagnosed at <56 years (Early Onset Prostate Cancer Study, EOPCFS; n = 631); (ii) a population-based case-control study consisting of cases diagnosed in Melbourne and Perth (Risk Factors for Prostate Cancer Study, RFPCS; n = 702). Cases were identified from population cancer registries and had histopathologically confirmed PrCa (excluding tumors with Gleason scores of <5) and were diagnosed at <70 years with sampling stratified by age at diagnosis; (iii) a prospective cohort study of 17,154 men aged 40-69 years at recruitment between 1990 and 1994 (Melbourne Collaborative Cohort Study, MCCS; n = 378). Controls were selected from the RFPCS study, in which they were identified through government electoral rolls and frequency matched to the age distribution of the RFPCS cases (n = 667) together with a random sample from the MCCS cohort (n = 981).
Stage 3 included samples from 21 PrCa case-control studies from groups in the PRACTICAL Consortium (Supplementary Table 4) .
All studies were approved by the ethics committees local to each study center, and study participants gave written informed consent.
Genotyping. Stage 2 genotypes were generated using an Illumina iSELECT array. SNPs were selected on the basis of the stage 1 results to include those with (i) a 1-d.f. P trend < 0.059 (n = 34,484) and (ii) a 2-d.f. genotype test P < 0.01 (n = 2,202). We also included (iii) all SNPs from the 1M array in LD blocks defined around 'hits' from stage 1, defined as a SNP with P trend < 0.0001; (iv) all SNPs from the Illumina 1M array on 8q24; (v) all SNPs from the 550k array in the HLA region and (vi) all SNPs significant in the CGEMS GWAS with P trend <0.01. We also included a further set of SNPs of interest in collaboration with CGEMS group (these were not considered in this paper; results to be reported separately). For analysis, we used samples on which genotypes could be called for at least 97% of SNPs at a confidence score of ≥0.25. Data were generated on 43,671 of 47,120 SNPs.
To identify close relatives we computed identity-by-state (IBS) probabilities for all pairs. We identified 93 cryptic duplicate samples (or monozygotic twins) or probable brothers (IBS > 0.86). In each case we excluded the individual with the lower call rate. By computing IBS scores between participants and individuals in HapMap and using multi-dimensional scaling, we identified 252 individuals who appeared to have substantial Asian or African ancestry (approximately >10% non-European ancestry). We removed 14 cases with a substantial level of heterozygosity on X (16-39%; including 3 known cases of
